

## Fostering research capacity, networking and project management through phase I-IIB clinical trials of candidate malaria vaccine GMZ2

This project will develop a promising candidate malaria vaccine GMZ2 (Hybrid combination of GLURP and MSP3), taking it through phase Ib clinical trial in Gabonese children, and multi-centre phase IIB trials in Burkina Faso, Gabon, Gambia and Uganda. Through this process, capacity building will be achieved by infrastructural upgrades, both short and long term professional training, and the consortium will enhance its networking activities leading to sharing of skills and resources that will ensure that the junior sites are developed towards level 4 sites.

The project is broken into four work packages: Project Management, Clinical Trials, Capacity Building and Networking.

It will be conducted by a consortium of seven partners: AMANET (Tanzania), EMVI (Denmark), CNRFP (Burkina Faso), UKT (Germany), ASH (Gabon), MUK (Uganda), MRC (The Gambia).



Ramadhani Noor, project coordinator

### Objectives

The overall aim of this project is to develop an effective malaria vaccine that is safe, effective, and can be integrated into the expanded programme on immunisation within African countries. We propose to do this work in four work packages with each package having specific objectives as follows:

#### Project Management

- To set up an efficient project management system that will drive clinical trials of GMZ2, improve partnerships through coordination, capacity building and networking
- To enhance the capacity of AMANET as a sponsor for GCP clinical trials in Africa.

#### Clinical trials

- To contribute to the fight against malaria through accelerated development of candidate malaria vaccine GMZ2 through age de-escalation safety, immunogenicity and limited efficacy trials at the four African trial sites
- To develop sustainable clinical trial capability that will contribute to other

clinical research activities of public health benefit in Africa.

#### Capacity Building

- To contribute to capacity development of African sites able to undertake GCP trials through human resource training, mentorship, infrastructural development and implementation of clinical studies
- To contribute with other EDCTP African projects involved in Capacity Building in Africa to the cross-fertilisation of experience from other PRD vaccines projects (HIV, Tuberculosis) or other malaria prevention tools/malaria treatment projects to the training of clinical trialists (project management, financial management, GCP training, GLP training, monitoring training)
- To participate with other EDCTP projects in capacity building of ethical review of clinical trials.

#### Networking

- To enhance the pre-existing collaboration and information sharing among partners through specific project activities
- To create a platform and modalities for new networks within the host country of the trials and the regions at large
- To create attachment opportunities for sharing best research practices and enhanced networking among trial sites in Africa.

Developing an effective vaccine against malaria while building capacity and enhancing networking among African and European institutions

## Project at a glance

### Official title

Fostering research capacity, networking and project management through phase I-IIb clinical trials of candidate malaria vaccine GMZ2

### Project Coordinator

Ramadhani Noor  
African Malaria Network Trust, Tanzania

### Participants

- Babatunde Egeruan Imoukhuede, UK
- Sodiomon Sirima, Burkina Faso
- Saadou Issifou, Gabon
- Fred Kironde, Uganda
- Benjamin Mordmuller, Germany
- Kalifa Bojang, The Gambia
- James Oloo, Tanzania
- Ramadhani Noor, Tanzania
- Nathalie Imbault, Denmark
- Roma Chilengi, Tanzania

### Total budget

€ 9,863,901

### EDCTP budget

€ 5,140,147

### Project duration

60 months

### Start date

19 January 2009

### End date

18 January 2014



The consortium partners during the kick off meeting

## Expected outcomes

The main expected outcomes include:

1. An established network with efficient project management capabilities
2. Clinical trial results from phase I and II of a promising candidate malaria vaccine
3. At least two PhDs, 3 MScs and 1 post doctoral fellow
4. All four clinical trial sites at Uganda, Gambia, Gabon and Burkina Faso having sufficient infrastructure and skills to conduct malaria vaccine trials to GCP standards.

Through this project, key EDCTP goals will be achieved. First, it is a partnership involving an NGO, four African research institutions, two European institutions and is supported by at least three European Member States.



EUROPEAN  
COMMISSION

Supported by the EU DG Research

### For more information

EDCTP The Hague

T +31 70 344 0880/0897

F +31 70 344 0899

E [info@edctp.org](mailto:info@edctp.org)

I [www.edctp.org](http://www.edctp.org)